Clin Chim Acta:基线C反应蛋白较高与缺血性卒中风险增加相关

2015-12-27 MedSci MedSci原创

背景:有关超敏C-反应蛋白(hs-CRP)和卒中的风险之间的研究结果是相互矛盾的。目标:为确定基线hs-CRP升高的是否是不同类型的卒中的独立危险因素。方法:系统搜索PubMed、EMBASE、Cochrane图书馆、中国知网和万方数据库中2015年1月前发表的前瞻性观察性研究。研究报告超敏c反应蛋白水平和hs-CRP和不同卒中亚型的水平和校正风险评估值。总结果用校正风险比(RR)来表示,及相应的

背景:有关超敏C-反应蛋白(hs-CRP)和卒中的风险之间的研究结果是相互矛盾的。

目标:为确定基线hs-CRP升高的是否是不同类型的卒中的独立危险因素。

方法:系统搜索PubMed、EMBASE、Cochrane图书馆、中国知网和万方数据库中2015年1月前发表的前瞻性观察性研究。研究报告超敏c反应蛋白水平和hs-CRP和不同卒中亚型的水平和校正风险评估值。总结果用校正风险比(RR)来表示,及相应的95% CI表示为最高与最低的hs-CRP范畴。

结果:共有十二项研究,66560个受试者,其中2269名发生卒中,2436名为缺血性卒中和655名为出血性卒中。在固定效应模型,比较最高和最低的hs-CRP时,缺血性脑卒中的总RR值为1.46(95% CI 1.27-1.67)。各种卒中和出血性中风的总RR分别为1.23(95%CI:0.997-1.51)和0.82(95% CI 0.59-1.13)。男性缺血性卒中的风险似乎更高(RR 1.66;95% CI 1.23-2.24)。

结论:基线hs-CRP水平较高与缺血性卒中风险增加有关,但与出血性脑卒中无明显相关。

原文出处:

Zhou Y, Han W, et al. Hs-CRP in stroke: A meta-analysis. Clin Chim Acta. 2015 Nov 26.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849521, encodeId=b46a184952153, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 17 14:29:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892712, encodeId=7edb1892e122c, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 28 21:29:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806055, encodeId=d4471806055a0, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Nov 07 11:29:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281199, encodeId=529b128119935, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297807, encodeId=0d75129e80717, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-08-17 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849521, encodeId=b46a184952153, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 17 14:29:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892712, encodeId=7edb1892e122c, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 28 21:29:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806055, encodeId=d4471806055a0, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Nov 07 11:29:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281199, encodeId=529b128119935, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297807, encodeId=0d75129e80717, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849521, encodeId=b46a184952153, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 17 14:29:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892712, encodeId=7edb1892e122c, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 28 21:29:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806055, encodeId=d4471806055a0, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Nov 07 11:29:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281199, encodeId=529b128119935, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297807, encodeId=0d75129e80717, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849521, encodeId=b46a184952153, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 17 14:29:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892712, encodeId=7edb1892e122c, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 28 21:29:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806055, encodeId=d4471806055a0, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Nov 07 11:29:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281199, encodeId=529b128119935, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297807, encodeId=0d75129e80717, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849521, encodeId=b46a184952153, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Aug 17 14:29:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892712, encodeId=7edb1892e122c, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Mon Dec 28 21:29:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806055, encodeId=d4471806055a0, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Mon Nov 07 11:29:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281199, encodeId=529b128119935, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297807, encodeId=0d75129e80717, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Tue Dec 29 07:29:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]

相关资讯

Am Heart J: IL-6和CRP是房颤患者死亡和心血管事件发生的危险因素(RE-LY研究)

背景:炎症与心血管疾病和房颤(AF)相关。这项研究中,研究者评估房颤患者炎症标志物和未来心血管事件的发生的相关性。方法:随机化分析IL-6,CRP(n= 6187)和纤维蛋白原(n = 4893)。应用Cox模型和C-statistics评估预后。结果:校正临床危险因子后,IL-6与卒中或全身性栓塞,严重出血,血管性死亡和复合血栓栓塞预后(缺血性卒中,全身性栓塞,心肌梗死,肺栓塞和血管性死亡)相关

Am J Cardiol:肥胖为高敏C反应蛋白升高重要预测因素

  美国学者的一项研究表明,肥胖为高敏C反应蛋白(hs-CRP)升高的最重要预测因素。论文于2012年11月5日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究从前瞻性人群中纳入289例患者。对多种潜在预测因素与hs-CRP的相关性进行评估。对潜在混淆因素进行校正之后,利用双变量和多变量线性回归模型对肥胖、体育活动、抑郁及其他数种潜在因素进行分析。

Thorax:C反应蛋白和慢性阻塞性肺疾病(COPD):孟德尔随机化方法

背景:C反应蛋白(CRP)和慢性阻塞性肺疾病(COPD)之间是否有因果关系并不清楚。作者使用孟德尔随机化方法评价了遗传性血清高CRP引起COPD的假设。方法:作者检测了血清高敏CRP,CRP基因型的四个单核苷酸多态性,在哥本哈根心脏研究7974例和哥本哈根普通人群研究32 652例中筛选出肺功能确定由于COPD住院的COPD。结果:血清CRP>3 mg/l者和<1 mg/l者患COPD

冠心病患者动脉弹性与血清高敏C反应蛋白和基质金属蛋白酶9的相关性

 动脉系统作为一个整体,其结构和功能改变在心血管疾病发生发展中极其关键。近年研究发现动脉弹性可以反映动脉系统整体结构与功能变化,是早期血管病变的特异性和敏感性指标。它的改变早于疾病临床症状和体征出现并且是预测未来心血管事件的敏感指标。动脉弹性减退是多种危险因素对血管壁损害的综合反映[4] ,其中慢性系统性炎症反应是动脉结构与功能的重要影响因素。同时动脉粥样硬化被广泛地认为是一种慢性炎

7种方法降C反应蛋白 让心梗远离你

多年来医生都专注于用基本措施来评估患者的健康状况,如血压、体重、胆固醇水平等。但近年来更多的研究发现针对心脏健康出现了一种新的最有价值预测方法:C反应蛋白(CRP)。据menshealth.com网站报道,尽管早在1930年医生们就发现了这种由肝脏生成的血浆蛋白,但只是在前几年医学界才发现它很重要。现在医生已了解到体内的CRP水平能帮助评估慢性炎症及

PNAS:欺负人有益健康?

据《科学》(Science)网站报道,在学校里受欺负(Bullying)会使儿童产生长期的阴影,这些儿童长大以后更容易抑郁和产生自杀倾向。科学家们还发现,童年常被欺负的孩子长大以后更容易生病、出现头疼和胃部问题。现在一项新研究揭示了上述现象背后的原因,研究显示受欺负的儿童中疾病指标C反应蛋白( CRP )高于正常水平,而且他们长大以后依然如此。反倒是那些欺负人的孩子看起来更为健康。 在许多慢性病中